Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2003

View Archived Issues

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Immune Response

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: AVI BioPharma

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Chrysalis BioTechnology

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Cubist Pharmaceuticals

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: CytRx

Adenoviral gene therapy improves myocardial perfusion in stable angina

Britannia and US WorldMeds sign licensing agreement for lofexidine

Enrollment completed in phase IIa trial of DB-289

Second of three dose levels of Oxycyte completed in phase I study

Merck presents three series of IGF-1R and IRR inhibitors

GSK scientists identify novel Lp-PLA2 inhibitors for use in atherosclerosis therapy

New HCV NS3-NS4A protease inhibitors under study at Vertex

New IKK-2 kinase inhibitors and their use covered by GSK patent

ImmunoGen scientists design new prodrugs of CC-1065 analogues

Sankyo patent describes novel IL-4 and/or IL-10 production promoters

Boehringer Ingelheim researchers present new cathepsin inhibitors

Novel antihistaminic agents prepared and tested at Sun Pharmaceutical

Merck KGaA scientists describe modulators of 5-HT activity and their use

BioBalance commences enrollment in IBS trial of Probactrix

Cengent demonstrates efficacy of anthrax lethal factor inhibitor in animals

Medivir and Roche restructure HIV alliance, enter research agreement for HCV

Dosing complete in phase I study of MM-093

Twelve-month data favor transition to bivalirudin as standard treatment

Arixtra receives European approval for extended prophylaxis of VTE

Positive results announced for aliskiren in hypertension

Potential new antidepressant, BMS-296859, with dual mechanism of action

Strong antitumor effects demonstrated for humanized anti-TF monoclonal antibody

Candidate NR2B antagonist for chronic/neuropathic pain states

Small-molecule HDAC inhibitor JNJ-16241199, a potent, orally active antitumor agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...